Pilot study of dMD-002 in patients with neurovascular bundles injury during radical prostatectomy -

Pilot study of dMD-002 - A study on the efficacy and safety of dMD-002 in patients with neurovascular bundles injury during radical prostatectomy -

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2022210040

Enrollment

Registered

2021-10-01

Start date

2021-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate cancer

Interventions

The cut dMD-002 is implanted to cover the nerve injury, tear, or defect, and is fixed by suturing to the surrounding tissue in two or more places.

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with prostate cancer (2) Patients scheduled for radical prostatectomy (non-nerve sparing or unilateral nerve-sparing) by robot-assisted laparoscopic surgery etc.

Exclusion criteria

Exclusion criteria: (1) Patients required radiation therapy, endocrine therapy or antineoplastic therapy before or after radical prostatectomy (2) Patients taking PDE5 inhibitors (3) Patients using negative pressure erection apparatus

Design outcomes

Primary

Measure	Time frame
Efficacy Change in EHS Change in IIEF EF Change in EPIC sxual function(Q17 to 23) Safety Advere event defect	—

Contacts

Public ContactPublic relations

Mochida Pharmaceutical Co., Ltd.

webmaster@mochida.co.jp+81-3-3225-6303

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026